Boehringer Ingelheim has become the latest company to enter the growing market of tumour agnostic medicines with the first KRAS inhibitor. …
Boehringer Ingelheim looking to bring tumour-agnostic trials to Australia
October 31, 2019 Latest News
Latest Video
New Stories
-
PHARMAC switch now blamed for three deaths
November 14, 2019 - - Latest News -
7CPA deal unlikely in 2019
November 14, 2019 - - Latest News -
New report highlights system challenge for Alzheimer's treatment
November 14, 2019 - - Latest News -
Official opening of new Merck headquarters
November 13, 2019 - - Latest News -
AusBiotech releases update on local regenerative medicine sector
November 13, 2019 - - Latest News -
Department confirms emergency supply arrangements for bushfire areas
November 13, 2019 - - Latest News -
Mark Glover: The tech opportunity for clinical trials
November 13, 2019 - - Latest News